Acurex Biosciences Corporation, a biopharmaceutical company with a mission to stop neurodegeneration before it begins, announces the appointment of renowned biopharmaceutical industry leader Dr. Robert Booth to its Board of Directors.
Dr. Booth, distinguished for his invaluable contributions to the biopharmaceutical industry, brings over 30 years of experience in drug discovery, development, and executive leadership. Dr. Booth earned his Ph.D. in biochemistry from University College London and rose to Senior Vice President at F. Hoffmann-La Roche AG early in his career. As the Chief Scientific Officer at Celera Genomics, Dr. Booth initiated the BTK inhibitor program that led to the development of Imbruvica, a revolutionary treatment for many hematological cancers. This groundbreaking inhibitor was later licensed to Pharmacyclics, where Dr. Booth served on the Board of Directors until its acquisition by AbbVie.
Within academia, Dr. Booth has been an adjunct professor at Stanford University School of Medicine where his work led him to co-found CuraSen Therapeutics, Inc. He also served as the founder and CEO of Virobay Inc. and was an instrumental operating partner and senior advisor at TPG Biotech. He presently serves on the boards of Thryv Therapeutics and Summit Therapeutics, bringing his industry expertise to provide strategic direction.
On his appointment to Acurex’s board, Dr. Booth commented, “I am truly excited to join the board of Acurex Biosciences. The company’s unique approach to neurodegeneration, backed by solid science and a dedicated team, aligns with my passion for innovative and impactful drug development. I look forward to contributing to Acurex’s trailblazing work, which holds enormous promise for patients affected by neurodegenerative disorders.”
Acurex CEO and CSO William D. Shrader, Ph.D., expressed his enthusiasm stating, “Dr. Booth’s deep insights based on extensive experience in building successful biopharmaceutical companies will be instrumental in Acurex’s pursuit to reshape the disease landscape for neurodegenerative disorders. We are thrilled to be able to attract such an esteemed industry leader and welcome Dr. Booth to our Board of Directors.”
Read more about Bioscience companies here:
Rxilient Biotech and Junshi Biosciences partner to develop and commercialize Toripalimab
Akston Biosciences appoints John T. Preston as Board of Directors
Flagship Biosciences Acquires Interpace Pharma Solutions expanding portfolio of analytics services
